Musette P, Galelli A, Chabre H, Callard P, Peumans W, Truffa-Bachi P, Kourilsky P, Gachelin G
Unité de Biologie Moléculaire du Gène, unité INSERM U277, Institut Pasteur, Paris, France.
Eur J Immunol. 1996 Aug;26(8):1707-11. doi: 10.1002/eji.1830260807.
The V beta 8.3-specific superantigenic lectin Urtica dioica agglutinin (UDA) was used to delete the V beta 8.3+ T cells in MRL lpr/lpr mice. In contrast to the systemic lupus erythematosus-like pathology which progresses with age in the phosphate-buffered saline-injected MRL lpr/lpr controls, UDA-treated animals did not develop overt clinical signs of lupus and nephritis. The pathogenic T cell clones thus reside within the V beta 8.3+ T cell population, which includes an expanded T cell clone described previously. Finally, UDA alters the production of autoantibodies in a sex-dependent manner.
Vβ8.3特异性超抗原凝集素荨麻凝集素（UDA）用于清除MRL lpr/lpr小鼠中的Vβ8.3+ T细胞。与注射磷酸盐缓冲盐水的MRL lpr/lpr对照小鼠中随年龄增长而发展的系统性红斑狼疮样病理不同，经UDA处理的动物未出现明显的狼疮和肾炎临床症状。因此，致病性T细胞克隆存在于Vβ8.3+ T细胞群体中，其中包括先前描述的一个扩增的T细胞克隆。最后，UDA以性别依赖的方式改变自身抗体的产生。
